^
Association details:
| Biomarker: | EGFR exon 19 deletion + EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1223P - Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG)
Published date:
09/13/2021
Excerpt:
...pts with EGFRm+ NSCLC (Del19 or L858R) treated with 1st-line afa/2nd-line osi in regular clinical practice (n = 191; all T790M+)...ORR with afa and osi was 74% and 45%....These data support the previous GioTag study and show encouraging activity of sequential afa/osi in pts with EGFRm+ NSCLC and acquired T790M.
Trial ID:
